Logo

American Heart Association

  15
  0


Final ID: MP1494

Not All LDLs are Created Equal: Discordance Between Calculated LDL-C Estimates and Incident ASCVD in the Multi-Ethnic Study of Atherosclerosis

Abstract Body (Do not enter title and authors here): Introduction: The Friedewald equation (F-LDL-C) is the most widely used estimate of LDL-cholesterol (LDL-C), but it can be inaccurate at high TG and low LDL-C. The Martin-Hopkins (MH-LDL-C) and the Sampson (S-LDL-C) equations more accurately estimate LDL-C. Individuals with discordant LDL-C estimates may be undertreated for their ASCVD risk, depending on the equation used. The association of discordance in LDL-C estimates with ASCVD risk is not well established.
Hypothesis: Individuals with greater discordance in LDL-C estimates are at higher risk for incident ASCVD
Methods: We estimated F-LDL-C, MH-LDL-C, and S-LDL-C in 6636 patients (mean 61.6 years, 47% male) with TG < 400 mg/dL in the Multi-Ethnic Study of Atherosclerosis. We divided the cohort into quintiles (Q1-Q5) of LDL-C discordance, measured by the absolute difference of LDL-C values between equations (MH-LDL-C minus F-LDL-C, S-LDL-C minus F-LDL-C, MH-LDL-C minus S-LDL-C). We examined the association of characteristics (sex, age, race, BMI, diabetes, hypertension, tobacco use) with quintile of discordance using the Jonckheere-Terpstra test. We used multivariable adjusted Cox regression models to assess the hazard associated with quintiles of discordance for ASCVD events (MI, stroke, CV death, or revascularizations).
Results: Greater LDL-C discordance (when MH-LDL-C and S-LDL-C were higher than F-LDL-C) was significantly associated with male sex, higher BMI, diabetes, hypertension, and tobacco use in unadjusted models. There were 1,275 ASCVD events over a median follow up of 18.4 years. The distribution of intra-quintile LDL-C values grew exponentially in Q5 across all groups, with the MH – F cohort demonstrating the greatest LDL-C range (absolute difference of 31.2 mg/dL). In fully adjusted Cox models, those in Q4 (HR 1.23, 95% CI 1.03-1.48) and Q5 (HR 1.28, 95% CI 1.06-1.55) of LDL-C discordance (where MH-LDL-C was higher than F-LDL-C) had a higher hazard for ASCVD events. Greater discordance between S-LDL-C and F-LDL-C trended towards increased ASCVD risk, but the results were not statistically significant.
Conclusions: Greater LDL-C discordance where MH-LDL-C was higher than F-LDL-C is independently associated with greater ASCVD, after adjustments for variables associated with higher discordance. Our findings favor using newer equations to estimate LDL-C and suggest that this high-risk group is at risk for being undertreated if targeting the widely used F-LDL-C estimates.
  • Canga, Sophia  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Quispe, Renato  ( Johns Hopkins Medicine , Baltimore , Maryland , United States )
  • Muthukumar, Alagarraju  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Joshi, Parag  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Macpherson, Nicholas  ( Connected Cardiovascular Care , Dallas , Texas , United States )
  • Vasquez, Nestor  ( Johns Hopkins Medicine , Baltimore , Maryland , United States )
  • Khera, Amit  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Rohatgi, Anand  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Martin, Seth  ( Johns Hopkins Medicine , Baltimore , Maryland , United States )
  • Jones, Steven  ( Johns Hopkins Medicine , Baltimore , Maryland , United States )
  • Ayers, Colby  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Navar, Ann Marie  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Author Disclosures:
    Sophia Canga: DO NOT have relevant financial relationships | Renato Quispe: No Answer | Alagarraju Muthukumar: DO NOT have relevant financial relationships | Parag Joshi: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Consultant:New Amsterdam Pharma:Past (completed) ; Consultant:Kaneka:Past (completed) ; Consultant:Novartis:Past (completed) ; Research Funding (PI or named investigator):Kaneka:Past (completed) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) | Nicholas Macpherson: No Answer | Nestor Vasquez: No Answer | Amit Khera: DO NOT have relevant financial relationships | Anand Rohatgi: DO have relevant financial relationships ; Consultant:Raydel:Past (completed) ; Consultant:JP Morgan:Past (completed) ; Consultant:Johnson and Johnson:Past (completed) ; Other (please indicate in the box next to the company name):LabCorp:Active (exists now) ; Other (please indicate in the box next to the company name):Quest:Active (exists now) ; Research Funding (PI or named investigator):CSL Behring:Past (completed) | Seth Martin: DO have relevant financial relationships ; Consultant:Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Care Access, Chroma, Bristol Myers Squibb, Heartflow, Kaneka, Merck, NewAmsterdam Pharma, Novartis, Novo Nordisk, Premier, Sanofi, Verve Therapeutics, :Past (completed) ; Ownership Interest:Corrie Health, Prevent Medical:Active (exists now) ; Other (please indicate in the box next to the company name):American Heart Association (Immediate Past Chair, EPI Statistics Committee):Active (exists now) ; Other (please indicate in the box next to the company name):National Lipid Association (SELA President):Active (exists now) ; Other (please indicate in the box next to the company name):Editorial Board Member (AJPC, EJPC, JCL):Active (exists now) ; Research Funding (PI or named investigator):National Institutes of Health, Patient-Centered Outcomes Research Institute, American Heart Association, American College of Cardiology:Active (exists now) ; Employee:Johns Hopkins School of Medicine :Active (exists now) ; Other (please indicate in the box next to the company name):National Institutes of Health Data Safety and Monitoring Board:Active (exists now) | Steven Jones: DO NOT have relevant financial relationships | Colby Ayers: DO have relevant financial relationships ; Consultant:NIH:Active (exists now) | Ann Marie Navar: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Consultant:Amgen, Arrowhead, Bayer, Esperion, Janssen, Eli Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Roche, Silence Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Esperion:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Cholesterol Chronicles: Lipid Markers and Cardiovascular Disease

Sunday, 11/09/2025 , 11:50AM - 01:05PM

Moderated Digital Poster Session

You have to be authorized to contact abstract author. Please, Login
Not Available